ALGS earnings date and last-quarter result: last quarter beat, P/E -0.59. Updated 2026-07-23.
Aligos Therapeutics (ALGS) Research Hub
Aligos Therapeutics (ALGS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.65 USD (-2.72%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.59, market cap 0.03B. This hub links to the full technical, earnings and options research available for ALGS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.65 USD (-2.72%) |
| 52-week range | 3.98 USD – 7.82 USD |
| Trend regime | Range |
| 14-day RSI | 30.5 (Bearish) |
| Trailing P/E | -0.59 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
Available research for ALGS
Covered Call on ALGS: how it works, illustrative setup around the real 4.65 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALGS: how it works, illustrative setup around the real 4.65 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALGS: how it works, illustrative setup around the real 4.65 USD price, max profit/loss, breakeven and when to use it. Educational.
ALGS technical analysis: range, last 4.65 USD, RSI 30.5, 52w range 3.98 USD–7.82 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ALGS in?
Aligos Therapeutics (ALGS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALGS in an uptrend or downtrend?
As of 2026-10-26, ALGS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALGS's trailing P/E ratio?
ALGS's trailing P/E is -0.59, with a market cap of 0.03B. See the earnings research page for full valuation detail.